Gossamer Calls It Quits On BTK Inhibitor Following Patient Deaths
The company will devote resources to its program to develop seralutinib in pulmonary arterial hypertension after announcing that it would discontinue GB5121 in CNS lymphoma.
The company will devote resources to its program to develop seralutinib in pulmonary arterial hypertension after announcing that it would discontinue GB5121 in CNS lymphoma.